Updates

·

HERGAI: Structure-Based hERG Inhibition Prediction Now Available on Vecura

This integration allows drug discovery researchers to assess hERG inhibition liability for small molecules directly within Vecura, utilizing a high-performance structure-based AI pipeline without the need for manual setup or complex infrastructure.

Vecura Team

What is HERGAI?

HERGAI is a specialized, structure-based AI classifier designed to predict the hERG potassium-channel inhibition liability of small molecules. By utilizing a fixed hERG receptor structure (7CN1) and AutoDock Vina, the model docks ligands and generates Protein-Ligand Extended Connectivity (PLEC) fingerprints, which are processed by a 4-model stacking ensemble. It helps users quickly assess whether a drug candidate poses a risk of cardiotoxicity. It is especially useful for drug discovery teams conducting early-stage lead optimization or pre-clinical ADMET profiling.

What can users do with HERGAI on Vecura?

With HERGAI on Vecura, users can:

  • Predict hERG inhibition probability for a list of SMILES strings.

  • Obtain a clear binary “Active” or “Inactive” cardiotoxicity label.

  • Streamline the ADMET profiling process by bypassing complex, manual docking workflows.

  • Leverage a benchmarked, high-performance structure-based method published in the Journal of Cheminformatics.

What the output means

The output provides a comprehensive prediction report, including the headlinednn_sc_prob(the final probability of being an hERG inhibitor), binary classification results based on a calibrated threshold, and individual probabilities from base classifiers (Random Forest, XGBoost, and a Keras DNN).

This output should be used to support scientific decision-making. It does not replace experimental validation.

Why this matters

The human Ether-a-go-go-Related Gene (hERG) potassium channel is a critical anti-target in drug discovery, as its blockade is a primary cause of drug-induced QT prolongation and lethal arrhythmias. Consequently, regulatory bodies require thorough screening of drug candidates for this liability.

Traditionally, structure-based docking approaches can be computationally intensive and complex to standardize. HERGAI provides a robust, pre-configured pipeline that simplifies this assessment, enabling researchers to identify potential cardiotoxicity risks earlier in the design cycle and prioritize safer chemical series for further development.

← Back to resources